https://doi.org/10.55788/b301086f
“HS is an incredibly active field at this moment, which is great for advancing and understanding the biology and the treatments that we will be able to use,” Prof. Alexandra Kimball (Harvard Medical School, MA, USA) expressed [1]. She revealed the results of secukinumab assessed in the SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) trials that recruited over 1,000 patients with HS at 219 sites worldwide. “This is only the second phase 3 programme we have ever seen in HS and the first one since 2016, so it really is a milestone,” Prof. Kimball highlighted. The 52-week studies assessed secukinumab after a loading phase administered at dosages of 300 mg every 2 (Q2W) or 4 weeks (Q4W) versus placebo, in adult patients with moderate-to-severe HS. Results of the primary endpoint at week 16, i.e. the proportion of patients achieving HiSCR, were presented.
Although the study was conducted during the COVID-19 pandemic, over 90% of the randomised participants completed week 16. Overall, the mean age was 36.2 years, with a higher proportion of older patients in the Q2W arm of SUNRISE (42.8% between 40 and 65 years). Most participants were women and over 50% weighed 90 kg or more. Hurley stage 2 and 3 proportions differed in SUNSHINE versus SUNRISE with 61.4% and 34.0% versus 56.7% and 40.5%, respectively.
In SUNSHINE, 45% in the Q2W arm achieved HiSCR versus 33.7% on placebo (P=0.0070), while the Q4W arm did not reach the predefined significance threshold. The SUNRISE participants of both treatment groups attained significant HiSCR results with 42.3% (Q2W; P=0.0149) and 46.1% (Q4W; P=0.0022) versus 31.2% on placebo. With regard to reduction of abscesses and nodules, the same treatment groups of the 2 studies demonstrated statistically significant results (see Figure).
Figure: Effect of secukinumab on abscess and inflammatory nodule [1]
*, significant compared with placebo; ns, non-significant compared with placebo.
AN, abscess and inflammatory nodule; ANCOVA, analysis of covariance; N, number of patients in group; Q2W, every 2 weeks; Q4W, every 4 weeks; SE, standard error; SEC, secukinumab 300 mg; Wk, week.
“The top line news here is fabulous: patients are getting better and both studies met their primary endpoint,” Prof. Kimball stressed. She furthermore accentuated that not only flaring decreased on the study drug but also pain. In the pooled analysis of pain development within the 2 trials, 38.9% in the Q2W programme achieved a 30% reduction of pain from baseline, significantly more than on placebo (26.9%; P=0.0031). Moreover, a clinically meaningful amelioration of quality-of-life was seen as early as week 2 in an exploratory analysis. As for adverse events, the studies did not reveal unexpected results. “Very reassuring safety data, consistent with what we have seen before and a very clean profile overall,” Prof. Kimball stated.
“We expect secukinumab to be a new, safe, and effective addition to our armamentarium in treating HS,” she concluded.
- Kimball A. LBA Secukinumab in moderate to severe hidradenitis suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE Phase 3 trials. D3T01.1A, EADV Congress 2022, Milan, Italy, 7–10 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise Next Article
Decreased overall survival in melanoma patients with low vitamin D »
« Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise Next Article
Decreased overall survival in melanoma patients with low vitamin D »
Table of Contents: EADV 2022
Featured articles
Letter from the Editor
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
AI machine learning algorithm useful in early detection of PsA
Novel Developments in Sun Protection
Myths regarding “health benefit” of suntan prevail in majority of population
Fern extract reverses severe actinic keratosis lesions
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Markedly lower skin cancer risk in vitiligo patients
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Best of the Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Genital psoriasis: high prevalence, often underdiagnosed
Decreased overall survival in melanoma patients with low vitamin D
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Roflumilast foam led to high response rates in seborrheic dermatitis
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Related Articles
November 5, 2022
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
November 5, 2022
Novel oral psoriasis drug maintains efficacy over 2 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com